Blinatumomab price

Blinatumomab is a revolutionary biologic used to treat a rare but challenging disease, acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia, ALL).

Belintuzumab has been launched in China, but it has not yet been included in medical insurance. The domestic price is about 10,000 yuan. Please consult the local hospital pharmacy for specific prices.

Acute lymphoblastic leukemia is a subtype of leukemia that mainly affects the malignant proliferation of lymphocytes. It usually occurs in both children and adults. Traditional treatments for leukemia include chemotherapy and bone marrow transplantation, but these treatments can be associated with serious side effects and have unstable therapeutic effects. The emergence of belintuzumab has brought new hope to patients with acute lymphoblastic leukemia.

Belintuzumab is a biological agent and a type of chimeric antigen receptor (chimeric antigen receptor, CAR-T) therapy. Its mechanism of action is very special. By connecting T cells and B cells, it enhances the recognition and attack of leukemia cells by the patient's immune system. Specifically, belintuzumab is a bispecific antibody that binds to CD3-positive T cells on one end and CD19-positive B cells on the other end. This allows the T cells to recognize leukemia cells and then release cytotoxic mediators to destroy these leukemia cells, thereby achieving a therapeutic effect.

Belintuzumab has achieved remarkable success in the treatment of acute lymphoblastic leukemia. It is widely used in relapsed or refractory Bcell acute lymphoblastic leukemia, especially in patients who have developed resistance to conventional treatments. In addition, belintuzumab has also been studied for other types of leukemia and lymphoma, broadening its scope of clinical application.